Sani Haider Kizilbash, MBBS

Sani Kizilbash practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Sani Kizilbash's NPI, 1518172782, was assigned on May 11, 2007. Sani Kizilbash graduated from Aga Khan Medical College in 2003. Sani Kizilbash holds Minnesota license 54474.

Sani Kizilbash's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Sani Kizilbash's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Sani Kizilbash is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Sani Kizilbash to 1 more clinical lab and 1 hospice, each named with a free account. Sani Kizilbash's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Sani Kizilbash practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Sani Kizilbash's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Sani Kizilbash is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Sani Kizilbash's licenses on file in 3 states: Minnesota, Florida and Michigan.

Dmand AI lists breast cancer, colorectal cancer, lung cancer, lymphoma and prostate cancer among the conditions Sani Kizilbash treats.

CMS data shows 40,380 Medicare services from Sani Kizilbash across 36 procedure codes in 2024, for 389 Medicare patients. Medicare paid $733,078 for them. Every service was in an office.

CMS counts 389 Medicare patients who saw Sani Kizilbash in 2024. The largest group is 65 to 74, with 227 patients. 61% of them have high blood pressure, and 59% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Sani Kizilbash's median patient age at 65, with 51% women.

In 2024, Sani Kizilbash wrote 114 Medicare Part D claims for 38 patients. 88% of them were for generic drugs. CMS names the drug for 50 of them, across 3 drugs with 11 or more claims each, at $587 in total drug cost. In 2022, CMS named 34 claims across 2 drugs.

Sani Kizilbash accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Sani Kizilbash as offering telehealth.

Dmand AI links 63 papers to Sani Kizilbash, published from 2013 to 2025. 2023 was the busiest year, with 8. The most frequent topics are Brain Neoplasms, Glioma and Glioblastoma. Sani Kizilbash has published most often in J Neurooncol. Sani Kizilbash's most frequent co-authors are Michael W. Ruff, MD, Joon H. Uhm, MD and Jian Li Campian, MD.

Dmand AI links Sani Kizilbash to 4 clinical trials, 2 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Astrocytoma, Glioblastoma and Lymphoma, Follicular.

CMS Open Payments shows 7 general payments to Sani Kizilbash from 4 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 87% of the total. SK Life Science, Inc. paid the most, $4,800.

Sani Kizilbash graduated from Aga Khan Medical College in 2003. Sani Kizilbash is a member of ACP, ASCO and Society of Neuroncology.

Sani Kizilbash is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.